Annexin accelerates patient recruitment in NEXUS study
Five patients treated for RVO and DR with no safety issues. Promising initial results observed. Recruitment continues.
See the latest news and media coverage for Annexin Pharmaceuticals. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing Annexin A5 therapeutics
annexinpharma.comLast updated
In short: Annexin Pharmaceuticals reported promising results in clinical trials for its drug candidate ANXV and secured new financing for further research.
Five patients treated for RVO and DR with no safety issues. Promising initial results observed. Recruitment continues.
They obtain a SEK 4 million bridge loan and plan a SEK 20 million rights issue to fund Phase 2a NEXUS; major shareholders committed about SEK 12 million.
Expands into diabetic retinopathy with Prof. Paulo Eduardo Stanga's team at The Retina Clinic London.
First two patients with DR and RVO show no safety issues and signals of efficacy including improved retinal perfusion after ANXV treatment. Study prepares for Phase 2b.
Annexin Pharmaceuticals has received approval for a clinical trial with the drug candidate ANXV from the German drug authority Bundesinstitut...
Annexin Pharmaceuticals AB (publ) today announces that the company has secured bridge financing of approximately SEK 4 million and intends to carry out a rights...
Get the detailed quarterly/annual income statement for Annexin Pharmaceuticals AB (publ) (ANNX.ST). Find out the revenue, expenses and profit or loss over the last fiscal...
Annexin Pharmaceuticals AB today announces favourable findings in the company's ongoing Proof of Concept Phase 2a study with the drug candidate ANXV in Diabetic Retinopathy...
Track Annexin Pharmaceuticals and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.